Original contribution
The implications of improved treatment of malignant salivary gland tumors by fast neutron radiotherapy

https://doi.org/10.1016/0360-3016(87)90222-7Get rights and content

Abstract

The conventional treatment for cancer of the salivary glands is surgery, with or without X ray therapy. In advanced tumors (Stage III and IV), local control and 5-year survival rates are less than 35%. Radical surgery severs the facial nerve in the majority of operations on parotid gland tumors. Local control of unresectable salivary gland tumors was achieved, in 74% of cases, by fast neutron therapy. From the MRC cyclotron at Hammersmith Hospital neutrons were given to 65 patients, with locally advanced or recurrent tumors, 89% of which were Stage IV. Local control and 5-year survival rates were 72% and 50%, respectively. The facial nerve was not damaged by neutron therapy. In patients with parotid gland tumors, 77% regained or maintained function. Function was lost in 14% through recurrence and 9% remained paralyzed. The results were achieved using beams from primitive machines with serious disadvantages. The results from neutrons implicate improvements for locally advanced tumors of non-epidermal origin in other sites of the body, especially with the high energy neutrons now available from modern cyclotrons.

References (25)

  • J.J. Batterman et al.

    Results of fast neutron teletherapy for locally advanced head and neck cancers

    Int. J. Radiat. Oncol. Biol. Phys.

    (1981)
  • O. Beahrs et al.

    American Joint Committee on Cancer

  • Cited by (63)

    • The efficacy of neutron radiation therapy in treating salivary gland malignancies

      2019, Oral Oncology
      Citation Excerpt :

      They found the highest relative biological difference (RBE) of 8 occurred for adenoid cystic carcinoma compared to 3–3.5 for most normal tissues. This discovery was followed by many nonrandomized neutron clinical trials that supported this conclusion [25,26]. Additional work has indicated that NRT has much higher linear energy transfer (LET) than conventional photon radiotherapy.

    • Salivary Gland Malignancies

      2015, Clinical Radiation Oncology
    • A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network)

      2014, Critical Reviews in Oncology/Hematology
      Citation Excerpt :

      The initial rationale was a reduced oxygen enhancement ratio, but the revised rationale suggests a higher relative biological effectiveness for slowly cycling tumors. While local control rates vary widely with photons and are generally poor, using neutrons in 213 patients, local control rates yielded 50% in squamous cell carcinomas and 80% in adenoid cystic carcinomas [33,50–52]. Battermann et al. indeed showed that the relative biological effect was highest for adenoid cystic carcinomas and reached 8 (i.e. neutrons were 8 times more efficient than photons for that histology) with fractionated neutron therapy [49].

    • Management of nasopharyngeal adenoid cystic carcinoma

      2013, Journal of Oral and Maxillofacial Surgery
    • Adenoid cystic carcinoma of the head and neck

      2012, American Journal of Otolaryngology - Head and Neck Medicine and Surgery
      Citation Excerpt :

      The improvement in local control after combined modality therapy compared with RT alone is probably due to a combination of improved efficacy and selection bias. Neutron RT may be associated with an improved probability of local–regional control when compared with conventional megavoltage photon and/or electron beams because of a lower oxygen enhancement factor (OER), less repair of sublethal damage, and less variation of radiosensitivity through the cell cycle [4,24,25]. Thus, neutrons may be preferable to treat large, slow-growing, hypoxic tumors such as advanced ACCs.

    • Salivary Gland Malignancies

      2012, Clinical Radiation Oncology: Third Edition
    View all citing articles on Scopus

    Work carried out at MRC Cyclotron Unit, Hammersmith Hospital, Ducane Road, London W 12 OHS.

    View full text